ESR1 and breast cancer: The phase III EMBER 3 clinical trial investigated imlunestrant versus fulvestrant versus imlunestrant plus abemacilib in patients with advanced ER+ breast cancer who have progressed on first-line endocrine therapy–based treatment and showed that imlunestrant had superior activity compared with fulvestrant in patients with an ESR1 mutation (39).